

USA, SEER 9, Black (1993-2012)

	Number of cases							Percentage				Incidence rates per million person-years								MV % 0-19	DCO % 0-19	
	Age group							0-14		0-19		Age-specific					Cumulative					
	0	1-4	5-9	10-14	15-19	0-14	0-19	All	Group	All	Group	0	1-4	5-9	10-14	15-19	0-14	ASR	0-19			0-14
I LEUKAEMIA	47	207	136	129	103	519	622	24.2	100.0	21.0	100.0	42.6	45.8	23.1	22.1	18.6	31.4	28.5	452	545	97.7	0.3
a. Lymphoid	16	146	98	80	37	340	377	15.8	65.5	12.8	60.6	14.5	32.3	16.6	13.7	6.7	20.5	17.4	296	329	99.5	0.0
b. Acute myeloid	24	51	25	35	36	135	171	6.3	26.0	5.8	27.5	21.7	11.3	4.2	6.0	6.5	8.3	7.9	118	150	98.2	0.6
c. CMD	0	2	7	9	16	18	34	0.8	3.5	1.2	5.5	-	0.4	1.2	1.5	2.9	1.0	1.4	15	30	85.3	0.0
d. MDS & other	2	2	2	4	11	10	21	0.5	1.9	0.7	3.4	1.8	0.4	0.3	0.7	2.0	0.6	0.9	9	19	90.5	0.0
e. Unspecified	5	6	4	1	3	16	19	0.7	3.1	0.6	3.1	4.5	1.3	0.7	0.2	0.5	1.0	0.9	14	17	89.5	5.3
II LYMPHOMA & RELATED	5	36	75	150	222	266	488	12.4	100.0	16.5	100.0	4.5	8.0	12.7	25.7	40.2	14.4	20.2	229	429	99.6	0.2
a. Hodgkin	0	2	21	69	134	92	226	4.3	34.6	7.6	46.3	-	0.4	3.6	11.8	24.2	4.7	9.1	79	200	100.0	0.0
b. Non-Hodgkin except BL	4	25	34	65	80	128	208	6.0	48.1	7.0	42.6	3.6	5.5	5.8	11.1	14.5	7.1	8.8	110	183	99.5	0.0
c. Burkitt (BL)	0	6	13	10	3	29	32	1.4	10.9	1.1	6.6	-	1.3	2.2	1.7	0.5	1.6	1.4	25	28	100.0	0.0
d. Lymphoreticular	1	3	5	1	1	10	11	0.5	3.8	0.4	2.3	0.9	0.7	0.8	0.2	0.2	0.6	0.5	9	10	100.0	0.0
e. Unspecified	0	0	2	5	4	7	11	0.3	2.6	0.4	2.3	-	-	0.3	0.9	0.7	0.4	0.4	6	10	90.9	9.1
III CNS NEOPLASMS	36	143	146	125	83	450	533	21.0	100.0	18.0	100.0	32.6	31.7	24.8	21.4	15.0	26.5	23.9	390	465	84.8	0.2
a. Ependymoma	5	22	14	6	4	47	51	2.2	10.4	1.7	9.6	4.5	4.9	2.4	1.0	0.7	2.9	2.4	41	45	98.0	2.0
b. Astrocytoma	13	69	63	70	43	215	258	10.0	47.8	8.7	48.4	11.8	15.3	10.7	12.0	7.8	12.6	11.5	186	225	95.0	0.0
c. CNS embryonal	9	25	25	17	10	76	86	3.5	16.9	2.9	16.1	8.2	5.5	4.2	2.9	1.8	4.6	3.9	66	75	100.0	0.0
d. Other gliomas	3	26	38	30	20	97	117	4.5	21.6	4.0	22.0	2.7	5.8	6.5	5.1	3.6	5.6	5.1	84	102	47.0	0.0
e. Other specified	2	0	3	2	5	7	12	0.3	1.6	0.4	2.3	1.8	-	0.5	0.3	0.9	0.4	0.5	6	11	91.7	0.0
f. Unspecified CNS	4	1	3	0	1	8	9	0.4	1.8	0.3	1.7	3.6	0.2	0.5	-	0.2	0.5	0.4	7	8	55.6	0.0
IV NEUROBLASTOMA	47	105	25	7	8	184	192	8.6	100.0	6.5	100.0	42.6	23.2	4.2	1.2	1.4	12.2	9.8	162	170	96.9	0.0
a. (Ganglio)neuroblastoma	47	103	25	6	5	181	186	8.4	98.4	6.3	96.9	42.6	22.8	4.2	1.0	0.9	12.0	9.5	160	164	97.3	0.0
b. Peripheral nervous	0	2	0	1	3	3	6	0.1	1.6	0.2	3.1	-	0.4	-	0.2	0.5	0.2	0.3	3	5	83.3	0.0
V RETINOBLASTOMA	31	51	1	0	0	83	83	3.9	100.0	2.8	100.0	28.1	11.3	0.2	-	-	5.7	4.4	74	74	90.4	0.0
VI RENAL TUMOURS	27	93	58	11	16	189	205	8.8	100.0	6.9	100.0	24.5	20.6	9.9	1.9	2.9	12.0	9.9	165	180	99.5	0.0
a. Nephroblastoma	27	91	57	3	3	178	181	8.3	94.2	6.1	88.3	24.5	20.1	9.7	0.5	0.5	11.4	9.0	156	159	99.4	0.0
b. Renal carcinoma	0	2	1	8	13	11	24	0.5	5.8	0.8	11.7	-	0.4	0.2	1.4	2.4	0.6	1.0	9	21	100.0	0.0
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
VII HEPATIC TUMOURS	4	12	2	7	8	25	33	1.2	100.0	1.1	100.0	3.6	2.7	0.3	1.2	1.4	1.6	1.5	22	29	93.9	3.0
a. Hepatoblastoma	4	11	2	4	0	21	21	1.0	84.0	0.7	63.6	3.6	2.4	0.3	0.7	-	1.3	1.0	18	18	100.0	0.0
b. Hepatic carcinoma	0	1	0	3	8	4	12	0.2	16.0	0.4	36.4	-	0.2	-	0.5	1.4	0.2	0.5	3	11	83.3	8.3
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
VIII BONE TUMOURS	0	2	23	57	64	82	146	3.8	100.0	4.9	100.0	-	0.4	3.9	9.8	11.6	4.2	5.9	70	128	99.3	0.0
a. Osteosarcoma	0	1	19	45	53	65	118	3.0	79.3	4.0	80.8	-	0.2	3.2	7.7	9.6	3.3	4.8	56	103	100.0	0.0
b. Chondrosarcoma	0	0	1	4	4	5	9	0.2	6.1	0.3	6.2	-	-	0.2	0.7	0.7	0.3	0.4	4	8	88.9	0.0
c. Ewing & related	0	0	1	3	3	4	7	0.2	4.9	0.2	4.8	-	-	0.2	0.5	0.5	0.2	0.3	3	6	100.0	0.0
d. Other specified	0	0	1	2	3	3	6	0.1	3.7	0.2	4.1	-	-	0.2	0.3	0.5	0.2	0.2	3	5	100.0	0.0
e. Unspecified	0	1	1	3	1	5	6	0.2	6.1	0.2	4.1	-	0.2	0.2	0.5	0.2	0.3	0.3	4	5	100.0	0.0
IX SOFT TISSUE SARCOMA	21	46	49	89	103	205	308	9.6	100.0	10.4	100.0	19.0	10.2	8.3	15.2	18.6	11.7	13.3	177	271	98.7	0.3
a. Rhabdomyosarcoma	5	34	34	27	22	100	122	4.7	48.8	4.1	39.6	4.5	7.5	5.8	4.6	4.0	5.9	5.5	87	107	98.4	0.8
b. Fibrosarcoma	5	4	3	10	11	22	33	1.0	10.7	1.1	10.7	4.5	0.9	0.5	1.7	2.0	1.3	1.4	19	29	100.0	0.0
c. Kaposi sarcoma	1	0	0	0	4	1	5	0.0	0.5	0.2	1.6	0.9	-	-	-	0.7	0.1	0.2	1	5	60.0	0.0
d. Other specified	9	5	9	43	49	66	115	3.1	32.2	3.9	37.3	8.2	1.1	1.5	7.4	8.9	3.6	4.8	57	101	100.0	0.0
e. Unspecified	1	3	3	9	17	16	33	0.7	7.8	1.1	10.7	0.9	0.7	0.5	1.5	3.1	0.9	1.4	14	29	100.0	0.0
X GERM CELL TUMOURS	29	15	5	29	75	78	153	3.6	100.0	5.2	100.0	26.3	3.3	0.8	5.0	13.6	4.7	6.7	68	136	94.1	0.0
a. CNS germ cell	3	2	2	8	13	15	28	0.7	19.2	0.9	18.3	2.7	0.4	0.3	1.4	2.4	0.9	1.2	13	25	89.3	0.0
b. Other extragonadal	21	9	0	3	12	33	45	1.5	42.3	1.5	29.4	19.0	2.0	-	0.5	2.2	2.2	2.2	29	40	86.7	0.0
c. Gonadal germ cell	5	3	3	17	42	28	70	1.3	35.9	2.4	45.8	4.5	0.7	0.5	2.9	7.6	1.6	2.9	24	62	100.0	0.0
d. Gonadal carcinoma	0	0	0	1	3	1	4	0.0	1.3	0.1	2.6	-	-	-	0.2	0.5	0.0	0.2	1	4	100.0	0.0
e. Unspecified gonadal	0	1	0	0	5	1	6	0.0	1.3	0.2	3.9	-	0.2	-	-	0.9	0.1	0.3	1	5	100.0	0.0
XI CARCINOMA & MELANOMA	3	6	8	44	124	61	185	2.8	100.0	6.3	100.0	2.7	1.3	1.4	7.5	22.4	3.2	7.6	52	165	98.9	0.0
a. Adrenocortical	0	3	2	0	0	5	5	0.2	8.2	0.2	2.7	-	0.7	0.3	-	-	0.3	0.2	4	4	100.0	0.0
b. Thyroid	0	0	2	12	36	14	50	0.7	23.0	1.7	27.0	-	-	0.3	2.1	6.5	0.7	2.0	12	45	100.0	0.0
c. Nasopharyngeal	0	0	1	11	17	12	29	0.6	19.7	1.0	15.7	-	-	0.2	1.9	3.1	0.6	1.2	10	26	100.0	0.0
d. Melanoma	1	1	1	1	3	4	7	0.2	6.6	0.2	3.8	0.9	0.2	0.2	0.2	0.5	0.2	0.3	3	6	100.0	0.0
e. Skin carcinoma	0	0	0	2	1	2	3	0.1	3.3	0.1	1.6	-	-	-	0.3	0.2	0.1	0.1	2	3	100.0	0.0
f. Other & unspecified	2	2	2	18	67	24	91	1.1	39.3	3.1	49.2	1.8	0.4	0.3	3.1	12.1	1.3	3.7	21	81	97.8	0.0
XII OTHER & UNSPECIFIED	1	2	0	1	4	4	8	0.2	100.0	0.3	100.0	0.9	0.4	-	0.2	0.7	0.3	0.4	4	7	100.0	0.0
a. Other specified	1	2	0	1	2	4	6	0.2	100.0	0.2	75.0	0.9	0.4	-	0.2	0.4	0.3	0.3	4	5	100.0	0.0
b. Other unspecified	0	0	0	0	2	0	2	-	-	0.1	25.0	-	-	-	-	0.4	-	0.1	-	2	100.0	0.0
TOTAL	251	718	528	649	810	2146	2956	100.0	100.0	100.0	100.0	227.4	158.9	89.7	111.2	146.5	127.9	132.1	1866	2599	95.6	0.2

Please consult the quality indicators for the constituent registries

USA, SEER 9, Black (1993-2012)

	Males										Females											
	Number of cases in age groups										M/F ratio		Number of cases in age groups									
	0	1-4	5-9	10-14	15-19	0-14	0-19	0-14	0-19	0-14	0-19	0	1-4	5-9	10-14	15-19	0-14	0-19	0-14	0-19		
I LEUKAEMIA	27	116	68	77	52	288	340	34.2	30.7	1.2	1.2	20	91	68	52	51	231	282	28.4	26.2		
a. Lymphoid	8	89	49	53	23	199	222	23.6	20.1	1.4	1.4	8	57	49	27	14	141	155	17.3	14.6		
b. Acute myeloid	15	21	15	16	15	67	82	8.1	7.4	1.0	0.9	9	30	10	19	21	68	89	8.5	8.3		
c. CMD	0	1	3	5	6	9	15	0.9	1.2	1.0	0.8	0	1	4	4	10	9	19	1.0	1.6		
d. MDS & other	1	1	0	2	7	4	11	0.5	0.9	0.7	1.1	1	1	2	2	4	6	10	0.7	0.9		
e. Unspecified	3	4	1	1	1	9	10	1.2	1.0	1.3	1.1	2	2	3	0	2	7	9	0.9	0.9		
II LYMPHOMA & RELATED	1	24	54	82	113	161	274	17.2	22.4	1.5	1.3	4	12	21	68	109	105	214	11.5	17.9		
a. Hodgkin	0	2	18	31	62	51	113	5.2	9.0	1.2	1.0	0	0	3	38	72	41	113	4.2	9.2		
b. Non-Hodgkin except BL	1	16	23	43	46	83	129	9.0	10.7	1.8	1.6	3	9	11	22	34	45	79	5.1	6.8		
c. Burkitt (BL)	0	4	9	6	1	19	20	2.1	1.7	1.9	1.7	0	2	4	4	2	10	12	1.1	1.0		
d. Lymphoreticular	0	2	3	1	0	6	6	0.7	0.5	1.5	1.2	1	1	2	0	1	4	5	0.5	0.5		
e. Unspecified	0	0	1	1	4	2	6	0.2	0.5	0.4	1.2	0	0	1	4	0	5	5	0.5	0.4		
III CNS NEOPLASMS	18	80	81	57	51	236	287	27.6	25.5	1.1	1.2	18	63	65	68	32	214	246	25.5	22.4		
a. Ependymoma	2	13	8	2	3	25	28	3.1	2.6	1.1	1.2	3	9	6	4	1	22	23	2.8	2.2		
b. Astrocytoma	6	39	33	32	22	110	132	12.8	11.7	1.0	1.0	7	30	30	38	21	105	126	12.4	11.3		
c. CNS embryonal	3	13	16	10	8	42	50	4.9	4.4	1.2	1.4	6	12	9	7	2	34	36	4.2	3.4		
d. Other gliomas	3	15	21	12	15	51	66	5.9	5.8	1.1	1.3	0	11	17	18	5	46	51	5.3	4.5		
e. Other specified	1	0	1	1	2	3	5	0.3	0.4	0.8	0.7	1	0	2	1	3	4	7	0.5	0.6		
f. Unspecified CNS	3	0	2	0	1	5	6	0.6	0.6	1.7	2.0	1	1	1	0	0	3	3	0.4	0.3		
IV NEUROBLASTOMA	30	54	8	2	5	94	99	12.4	10.0	1.0	1.1	17	51	17	5	3	90	93	11.9	9.5		
a. (Ganglio)neuroblastoma	30	52	8	1	2	91	93	12.1	9.5	1.0	1.0	17	51	17	5	3	90	93	11.9	9.5		
b. Peripheral nervous	0	2	0	1	3	3	6	0.4	0.5	-	-	0	0	0	0	0	0	0	-	-		
V RETINOBLASTOMA	14	23	1	0	0	38	38	5.1	4.0	0.8	0.8	17	28	0	0	0	45	45	6.3	4.9		
VI RENAL TUMOURS	15	44	18	6	6	83	89	10.5	8.6	0.8	0.8	12	49	40	5	10	106	116	13.5	11.3		
a. Nephroblastoma	15	42	18	2	1	77	78	9.8	7.7	0.8	0.8	12	49	39	1	2	101	103	13.0	10.2		
b. Renal carcinoma	0	2	0	4	5	6	11	0.7	0.9	1.2	0.8	0	0	1	4	8	5	13	0.5	1.1		
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
VII HEPATIC TUMOURS	3	8	0	3	5	14	19	1.8	1.8	1.3	1.4	1	4	2	4	3	11	14	1.3	1.3		
a. Hepatoblastoma	3	7	0	0	0	10	10	1.4	1.0	0.9	0.9	1	4	2	4	0	11	11	1.3	1.0		
b. Hepatic carcinoma	0	1	0	3	5	4	9	0.4	0.7	-	3.0	0	0	0	0	3	0	3	-	0.2		
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
VIII BONE TUMOURS	0	1	9	35	40	45	85	4.5	6.7	1.2	1.4	0	1	14	22	24	37	61	3.9	5.0		
a. Osteosarcoma	0	0	8	27	34	35	69	3.5	5.4	1.2	1.4	0	1	11	18	19	30	49	3.2	4.0		
b. Chondrosarcoma	0	0	0	3	3	3	6	0.3	0.5	1.5	2.0	0	0	1	1	1	2	3	0.2	0.2		
c. Ewing & related	0	0	1	2	3	3	6	0.3	0.5	3.0	6.0	0	0	0	1	0	1	1	0.1	0.1		
d. Other specified	0	0	0	2	0	2	2	0.2	0.2	2.0	0.5	0	0	1	0	3	1	4	0.1	0.3		
e. Unspecified	0	1	0	1	0	2	2	0.2	0.2	0.7	0.5	0	0	1	2	1	3	4	0.3	0.3		
IX SOFT TISSUE SARCOMA	9	24	35	48	53	116	169	12.9	14.3	1.3	1.2	12	22	14	41	50	89	139	10.5	12.2		
a. Rhabdomyosarcoma	1	19	26	16	9	62	71	7.1	6.2	1.6	1.4	4	15	8	11	13	38	51	4.7	4.7		
b. Fibrosarcoma	0	2	2	4	4	8	12	0.9	1.0	0.6	0.6	5	2	1	6	7	14	21	1.7	1.9		
c. Kaposi sarcoma	1	0	0	0	4	1	5	0.1	0.4	-	-	0	0	0	0	0	0	0	-	-		
d. Other specified	6	2	6	24	26	38	64	4.1	5.2	1.4	1.3	3	3	3	19	23	28	51	3.1	4.3		
e. Unspecified	1	1	1	4	10	7	17	0.8	1.4	0.8	1.1	0	2	2	5	7	9	16	1.0	1.4		
X GERM CELL TUMOURS	12	4	1	9	31	26	57	3.2	4.9	0.5	0.6	17	11	4	20	44	52	96	6.4	8.6		
a. CNS germ cell	1	0	0	6	10	7	17	0.7	1.4	0.9	1.5	2	2	2	2	3	8	11	1.0	1.0		
b. Other extragonadal	6	1	0	1	1	8	9	1.0	0.9	0.3	0.3	15	8	0	2	11	25	36	3.4	3.6		
c. Gonadal germ cell	5	2	1	2	18	10	28	1.3	2.4	0.6	0.7	0	1	2	15	24	18	42	1.9	3.4		
d. Gonadal carcinoma	0	0	0	0	1	0	1	-	0.1	0.0	0.3	0	0	0	1	2	1	3	0.1	0.2		
e. Unspecified gonadal	0	1	0	0	1	1	2	0.1	0.2	-	0.5	0	0	0	0	4	0	4	-	0.3		
XI CARCINOMA & MELANOMA	1	2	2	30	47	35	82	3.6	6.5	1.3	0.8	2	4	6	14	77	26	103	2.9	8.6		
a. Adrenocortical	0	0	0	0	0	0	0	-	-	0.0	0.0	0	3	2	0	0	5	5	0.6	0.5		
b. Thyroid	0	0	1	8	4	9	13	0.9	1.0	1.8	0.4	0	0	1	4	32	5	37	0.5	3.0		
c. Nasopharyngeal	0	0	1	10	11	11	22	1.1	1.7	11.0	3.1	0	0	0	1	6	1	7	0.1	0.6		
d. Melanoma	0	1	0	1	0	2	2	0.2	0.2	1.0	0.4	1	0	1	0	3	2	5	0.3	0.4		
e. Skin carcinoma	0	0	0	0	1	0	1	-	0.1	0.0	0.5	0	0	0	2	0	2	2	0.2	0.2		
f. Other & unspecified	1	1	0	11	31	13	44	1.3	3.5	1.2	0.9	1	1	2	7	36	11	47	1.2	3.9		
XII OTHER & UNSPECIFIED	1	0	0	1	2	2	4	0.2	0.3	1.0	1.0	0	2	0	0	2	2	4	0.3	0.4		
a. Other specified	1	0	0	1	1	2	3	0.2	0.3	1.0	1.0	0	2	0	0	1	2	3	0.3	0.3		
b. Other unspecified	0	0	0	0	1	0	1	-	0.1	-	1.0	0	0	0	0	1	0	1	-	0.1		
TOTAL	131	380	277	350	405	1138	1543	133.2	135.8	1.1	1.1	120	338	251	299	405	1008	1413	122.4	128.3		

Please consult the quality indicators for the constituent registries

USA, SEER 9, Black (1993-2012)

	Age group	Males	Females
Person-years	0	562 092	541 716
	1-4	2 298 885	2 218 648
	5-9	2 991 447	2 895 024
	10-14	2 968 723	2 869 674
	15-19	2 800 481	2 728 520
Total	0-14	8 821 147	8 525 062
	0-19	11 621 628	11 253 582
Average annual population	0-14	441 057	426 253
	0-19	581 081	562 679

Please consult the quality indicators for the constituent registries

USA, SEER 9, Black (1993-2012)

Registry	Period	Cases	%	Person-years	%
California, San Francisco	1993-2012	325	11.0	2 609 013	11.4
Connecticut	1993-2012	333	11.3	2 570 147	11.2
Georgia, Atlanta	1993-2012	1002	33.9	7 536 997	32.9
Hawaii	1993-2012	24	0.8	246 298	1.1
Iowa	1993-2012	96	3.2	709 758	3.1
Michigan, Detroit	1993-2012	888	30.0	6 943 974	30.4
New Mexico	1993-2012	39	1.3	361 795	1.6
Utah	1993-2012	31	1.0	263 745	1.2
Washington, Seattle	1993-2012	218	7.4	1 633 483	7.1
USA	1993-2012	2956	100.0	22 875 210	100.0

Please consult the quality indicators for the constituent registries